Clinical trials: Type One Diabetes Mellitus
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare the efficacy of postprandial plasma glucose of two treatment regimens in Chinese subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00593255
- Testing
- soluble human insulin, insulin aspart, insulin NPH
- Where
- 5 sites in China
- Volunteers
- 220 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes
The purpose of this study is to determine the safety and tolerability of pioglitazone-azilsartan, once daily (QD), in patients with type 2 diabetes mellitus.
- Trial name
- NCT01124656
- Testing
- Pioglitazone-Azilsartan
- Volunteers
- 26 people
- Sponsor
- Takeda
Weight Loss
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type…
- Trial name
- NCT07868835
- Testing
- VK2735
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
Diabetes, Diabetes Mellitus, Type 1
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01900834
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Type 2
Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
This study will evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.
- Trial name
- NCT00461136
- Testing
- Aliskiren
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
The primary objective is to demonstrate the non-inferiority at six months of a basal plus one insulin regimen (Lantus plus one injection of Apidra) compared with a biphasic insulin regimen (NovoMix 30) at controlling glycosylated…
- Trial name
- LanScape (NCT00965549)
- Testing
- INSULIN GLARGINE (HOE901), Insulin aspart, Insulin Glulisine
- Where
- 74 sites in Australia, United Kingdom
- Volunteers
- 463 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects
This trial is conducted in Europe and Asia. The aim of the trial is to investigate the influence of semaglutide on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02022254
- Testing
- semaglutide, metformin, warfarin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Weight Loss
VK2735 for Weight Management Phase 3
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- VANQUISH 1 (NCT07104500)
- Testing
- VK2735
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 4,500 people
- Sponsor
- Viking Therapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Asthma, Diabetes Mellitus
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma
- Trial name
- NCT00139659
- Testing
- Inhaled Insulin, Subcutaneous Insulin
- Where
- 102 sites in United States, Brazil and 3 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)
Primary: Effect on HbA1c over 48 weeks in insulin-treated patients with type 2 diabetes Secondary: Effect on glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides - Safety…
- Trial name
- NCT00288236
- Testing
- Rimonabant (SR141716)
- Where
- 12 sites in United States, Argentina and 10 more
- Volunteers
- 368 people
- Sponsor
- Sanofi
Sleep Initiation and Maintenance Disorders
Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus
The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- SAMS (NCT00464061)
- Testing
- Volinanserin
- Where
- 22 sites in United States, Argentina and 20 more
- Volunteers
- 1,847 people
- Sponsor
- Sanofi
Diabetes Mellitus Type 2
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
This study will assess the efficacy, safety and tolerability of increasing doses of GK Activator (2) in patients with type 2 diabetes whose condition has not been optimally controlled with one previous oral antihyperglycemic…
- Trial name
- NCT00366379
- Testing
- GK Activator (2)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes
The original protocol was a randomized, open-label, 3-way cross-over study with 9 scheduled visits. The visits comprised an initial screening visit, 3 treatment visits for the meal challenge followed by a 2-6-week blood-loss…
- Trial name
- NCT00570687
- Testing
- Technosphere Insulin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Obesity, Type 2 Diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight.
- Trial name
- NCT07564414
- Testing
- Cagrisema, Semaglutide
- Where
- 303 sites in United States, Argentina and 17 more
- Volunteers
- 2,500 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
One Drop Experts Program for Type 2 Diabetes Self-Management: Impact on A1c
The One Drop Experts Program for Type 2 Diabetes Self-Management Impact on A1c trial is a 12-week long, prospective, intent-to-treat study that aims to evaluate the impact of the One Drop app and Experts program on HbA1c levels…
- Trial name
- NCT02827669
- Testing
- One Drop Experts Program, One Drop Experts Program + Apple Watch
- Where
- United States
- Volunteers
- 297 people
- Sponsor
- Evidation Health
Diabetes Mellitus
Comparative Study of a Smartphone-Linked Self-Monitoring System Versus a Traditional One for Improving Metabolic Control and Compliance to Self-Monitoring of Blood Glucose
The purpose of this study is to demonstrate the superiority of iBGstar as a component of the diabetes treatment vs. traditional blood glucose self-monitoring system for improving glycemic control after 6 months in young patients…
- Trial name
- iNew Trend (NCT02073188)
- Testing
- iBGStar, Traditional Glucometer
- Where
- Italy
- Volunteers
- 186 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
This is an open-label study that will measure blood levels of different parts of a drug called GKS189075. People participating in this study will receive a single dose of 250mg GSK189075 by mouth.
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
- Trial name
- NCT00501462
- Testing
- GSK189075
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2…
- Trial name
- NCT06972459
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company